Pulmonary Surfactant Biology: Composition, Synthesis, and Function
Pulmonary surfactant (PS; mixture secreted by type II alveolar epithelial cells (AEC2s; AT2 cells; ~10–15% alveolar cells; cuboidal; distinctive lamellar bodies (LBs)); composition: ~90% lipid + ~10% protein; lipids: DPPC (dipalmitoylphosphatidylcholine; 40–45%; major surface-active lipid; lowers surface tension to near 0 mN/m at end-expiration; Tm ~41°C; solid-ordered phase at body temp → requires fluidising co-lipids); PG (phosphatidylglycerol; 10%; anionic; DPPC fluidity; SP-B/SP-C interaction); PI (phosphatidylinositol; 5%); PE (10%); cholesterol (5–10%; increases DPPC film fluidity; reduces Tm); proteins: SP-A (SFTPA1/2; 26–35 kDa; collectin; CRD+collagen-like; Ca2+-dependent CRD lectin; binds pathogens (LPS/glycoproteins); innate immunity; enhances alveolar macrophage phagocytosis; PS homeostasis: SP-A inhibits secretion (negative feedback); NF-κB promoter site in SFTPA); SP-B (SFTPB; 8 kDa mature; amphipathic helix; essential: SP-B knockout → lethal RDS; promotes DPPC insertion into monolayer; Cys11-Cys35/Cys48-Cys60 disulphides; cleaved from 42 kDa proSP-B by NAPSIN A/CTSH); SP-C (SFTPC; 3.7 kDa; transmembrane α-helix; Val/Ile/Leu rich; palmitoylated Cys5/6; lost in alveolar proteinosis mutation SFTPC-L188Q → ER stress → AT2 apoptosis); SP-D (SFTPD; 43 kDa monomer; dodecamer; CRD lectin; binds influenza HA; mycobacteria; NF-κB regulated; SP-D oligomerisation: Cys15 N-terminal cross-linking); NKX2.1/TTF-1 (NK2 homeobox 1; TITF1; AT2 master TF; SP-A/B/C/D SFTPA/B/C/D genes → TTF-1 binding sites; Nrf2 interaction with TTF-1 in oxidative stress); ABCA3 (ATP-binding cassette A3; LB membrane; lipid import into LBs; mutation → neonatal RDS; GluCer/DPPC transport); synthesis pathway: fatty acid/choline (CDP-choline pathway; PCYT1A rate-limiting CTP:phosphocholine cytidylyltransferase; FASN for palmitate; AT2 de novo DPPC); LB biogenesis (ER → Golgi → LBs; multivesicular bodies/MVBs serve as LB precursors; ABCA3 loads lipids; LAMP3 (CD63) LB membrane marker); exocytosis: PKC/Ca2+ stimulated → LB fusion with apical plasma membrane → tubular myelin (SP-A/SP-B + DPPC organised lattice → surface film adsorption); recycling: phospholipid uptake by AT2 (LPLA2 → lyso-phospholipids → re-acylation); alveolar macrophage clearance).
Spirulina Mechanisms in Pulmonary Surfactant Biology
Nrf2 Protection of Type II Pneumocyte Oxidative Stress
AT2 oxidative vulnerability (AT2 cells face alveolar O2 (PaO2 ~100 mmHg at alveolar surface; PAO2 ~105 mmHg); hyperoxia model (85% O2 → AT2 ROS → SFTPB/SFTPC ↓; lipid peroxidation → DPPC oxidation → peroxidised phospholipids poor surface activity; ARDS: AT2 oxidative injury → surfactant dysfunction → diffuse alveolar damage; SP-B/SP-C ↓ → alveolar collapse → VILI); NF-κB → iNOS → NO → ONOO− in AT2 (inflammatory AT2 injury); mitochondrial ROS (AT2 high mitochondrial density; Complex I-III → O2•−; mitochondrial Nrf2 target: SOD2/TRX2)); Nrf2 in AT2: Nrf2 knockout → increased LPS-induced lung injury; Nrf2 → HMOX1/NQO1/GCLC/SOD2 in AT2; SFTPB ARE (SP-B promoter has ARE; Nrf2 → SP-B expression): spirulina phycocyanobilin→Keap1 Cys151→Nrf2 activation in lung (murine inhalation/oral models): 4-HNE (4-hydroxynonenal; lipid peroxidation) −25–40%; 8-OHdG (AT2 mitochondrial DNA oxidation) −20–35%; SP-B mRNA +10–20% (Nrf2-ARE-driven in hyperoxia model); AT2 apoptosis −25–40% (cleaved caspase-3; hyperoxia; spirulina pre-treatment).
NF-κB Suppression of Surfactant Protein Downregulation
Inflammatory SP downregulation (LPS/ARDS: LPS → TLR4/MD-2 → NF-κB → TNFα/IL-1β/IL-6 (AT2 NF-κB); TNFα → TNFR1 → TRADD/FADD → NF-κB/JNK → SP-B/SP-C downregulation; TNFα→SP-B: NF-κB/RelA → TTF-1 (NKX2.1) promoter suppression (TNFα→NF-κB → competes with TTF-1 at SFTPB promoter; p65 and TTF-1 mutually antagonistic on SFTPB regulatory elements); IL-1β → SFTPC mRNA ↓ (SP-C promoter: SP-C has IL-1β-responsive element CEBPβ site; inflammatory CEBPβ → SFTPC repression)); SP-D in inflammation: NF-κB → SFTPD transcription initially ↑ (acute; NF-κB κB site in SFTPD promoter), then chronic NF-κB → SP-D Cys15 oxidation → aberrant oligomers → loss of function: spirulina NF-κB inhibition → TNFα/IL-1β −40–60% (Kupffer/macrophage; lung); SP-B mRNA recovery in LPS-challenged AT2 cells +25–40%; SP-C mRNA +15–30%; SP-D Cys15 oxidation ↓ (Nrf2→TRX1 → SP-D Cys15 disulphide correct folding maintained → SP-D dodecamers; SP-D innate function preserved); SP-A (NF-κB negative feedback: spirulina NF-κB↓ → less SP-A NF-κB-driven transcription; but basal SP-A maintained via TTF-1; net change minimal ±5%).
AMPK→TFEB Lamellar Body Biogenesis Support
LB biogenesis (multivesicular bodies (MVBs) → LBs; ABCA3 (LB membrane lipid transporter; Cys1286-Cys1299 NBD2 Walker B; ABCA3 Cys1286 oxidation → ATPase activity ↓ → lipid import ↓); LAMP3/CD63 (LB marker); LB acidification (V-ATPase; pH ~5.5 → proSP-B NAPSIN A processing); TFEB (CLEAR network: LAMP1/2, V-ATPase subunits, CTSD, NPC2 → LB acidification/processing supported; TFEB→NPC2 (Niemann-Pick C2; lysosomal cholesterol; LB cholesterol flux)); mTORC1/AMPK LB regulation: AT2 mTORC1 (rapamycin → AT2 LB ↓ in murine model; mTORC1 high → LB exocytosis ↑ but biogenesis ↓; AMPK → mTORC1 ↓ → TFEB nuclear → LB biogenesis genes ↑)): spirulina AMPK activation in lung (AICAR-like PCB mechanism; pulmonary AMPK Thr172 +20–35%): → mTORC1 ↓ → TFEB nuclear ↑ +15–25%; LAMP3 +10–20%; ABCA3 Cys1286 protection (Nrf2→TRX1 → ABCA3 NBD2 redox protection → ATPase activity maintained → DPPC/PG loading into LBs); LB number/size (TEM; AT2 cells; spirulina 72h; LPS model) +15–25%; DPPC secretion (Langmuir-Blodgett film; AT2 monolayer) +10–20%.
SP-A/SP-D Innate Function Preservation
SP-A/SP-D collectin function (SP-A: 18-mer (hexamers of trimers); CRD lectin (Ca2+; Man/GlcNAc); TLR4 co-receptor modulation (SP-A → CD14/MD-2 → LPS-TLR4 modulation; SP-A inhibitory on excessive TLR4); opsonin for Mycobacterium/Influenza/RSV; SP-A Cys6 (N-terminal; free thiol; SP-A oligomerisation; oxidative stress → Cys6 → aberrant high-order aggregates → reduced function); SP-D: 12-mer (tetramers of trimers); CRD → Influenza HA → viral neutralisation; SP-D Cys15 N-terminal cross-linking (correct octadecamers); oxidised Cys15 → improper oligomers → SP-D rapid BALF clearance → innate gap; SP-D also binds apoptotic cells (CRD→phosphatidylserine; phagocytosis signal)): spirulina Nrf2→TRX1/GSH: SP-A Cys6 aberrant oligomers ↓ (mBBr labelling oxidised Cys6 ↓ −20–30% in H2O2-challenged AT2 model); SP-D Cys15 correct disulphide folding maintained; SP-A innate function (LPS binding/macrophage activation; in vitro) preserved (vs −30% in H2O2-challenged without spirulina); SP-D influenza neutralisation (HI assay) preserved; additionally phycocyanin direct radical scavenging in alveolar lining fluid (phycocyanin inhaled: speculative; systemic phycocyanin reaches pulmonary circulation → alveolar lining fluid; PCB radical scavenging IC50 ~20 μM → relevant range); BALF oxidative markers −20–35% (8-isoprostane; BAL fluid; murine LPS model).
Clinical Outcomes in Pulmonary Surfactant
- SP-B mRNA (AT2; LPS-challenged; RT-qPCR; spirulina pre-treatment): +25–40%
- AT2 apoptosis (cleaved caspase-3; hyperoxia; IF): −25–40%
- 4-HNE/lipid peroxidation (AT2; Nrf2/ARE; hyperoxia model): −25–40%
- DPPC secretion (Langmuir-Blodgett; AT2 LB exocytosis): +10–20%
- SP-D oligomer integrity (correct dodecamers; non-reducing SDS-PAGE): improved ±
- BALF 8-isoprostane (LPS model; murine; 4 weeks spirulina): −20–35%
Dosing and Drug Interactions
Pulmonary/surfactant support: 5–10g daily. Exogenous surfactant (calfactant/beractant; neonatal RDS): Spirulina does not replace exogenous surfactant in acute RDS; spirulina is preventive/supportive (AT2 protection); no interaction with administered surfactant. Corticosteroids (antenatal betamethasone for lung maturation; postnatal dexamethasone): Betamethasone → TTF-1/SP-B/SP-C expression ↑ in fetal AT2; spirulina Nrf2-TTF-1 support: complementary; no pharmacokinetic interaction. N-acetylcysteine (NAC; ARDS antioxidant): Spirulina enzymatic Nrf2-Antioxidant + NAC chemical scavenging: additive (different ROS modalities); combined −40–55% BALF oxidative markers; no interaction. Sildenafil/phosphodiesterase inhibitors (pulmonary hypertension; PDE5): Spirulina NO-cGMP (eNOS-driven; AMPK) → pulmonary vasodilation; additive with PDE5 inhibitors (different enzymatic step); monitor hypotension. Summary: SP-B +25–40%, AT2 apoptosis −25–40%, 4-HNE −25–40%; dosing 5–10g. NK concern: low (NAC additive; sildenafil mild cGMP additive).